Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib plus intensive chemotherapy for newly diagnosed NPM1-mutated AML
2025-522279-27-00Phase 3Authorised
- Sponsor
- Syndax Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Revumenib + intensive chemotherapy with Placebo + intensive chemotherapy (2 arms). Primary endpoints: Event-free survival and Bone marrow MRD-negative complete remission rate. Planned start Apr 2026; status: authorised.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-522279-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522279-27-00.